workforce news
The MHRA's Yellow Card Scheme is the UK's system for collecting reports of suspected adverse drug reactions (ADRs). It has been running since 1964 — one of the oldest pharmacovigilance systems in the world — and community pharmacists are among its most important contributors.
Despite this, reporting rates from community pharmacy remain lower than the sector's potential. According to MHRA annual data, healthcare professional reports (including from pharmacists, doctors, and nurses) consistently make up a smaller proportion of Yellow Card submissions than patient self-reports. This guide covers what pharmacists should report, how to do it, and why it matters.
What to report
The Yellow Card Scheme accepts reports of:
- Suspected adverse drug reactions to any medicine, including over-the-counter products, herbal medicines, and complementary therapies
- Suspected ADRs to vaccines
- Suspected defective medicines (quality defects, contamination, packaging errors)
- Suspected counterfeit medicines
- Adverse incidents involving medical devices
A critical point: the MHRA does not require certainty that the medicine caused the reaction. A suspected link is sufficient. The scheme operates on the principle that under-reporting is a greater risk to public safety than over-reporting. If a pharmacist suspects a medicine may have contributed to an adverse event, a report is warranted.
What triggers a report in practice
Common community pharmacy scenarios that should prompt a Yellow Card report include:
| Scenario | Why it matters |
|---|---|
| Patient reports a new symptom after starting a medicine | May indicate an ADR not captured in the SmPC or occurring at unexpected frequency |
| Unexpected reaction to a well-established medicine | Even common drugs generate new safety signals — the denominator of exposed patients is large enough that rare reactions may only emerge through post-marketing surveillance |
| Reaction to a Black Triangle (▼) medicine | These are newly licensed medicines or those with a new indication, formulation, or route of administration — the MHRA specifically requests that ALL suspected ADRs for Black Triangle medicines are reported, not just serious ones |
| Suspected interaction between two medicines | Drug interactions discovered post-marketing often emerge through Yellow Card reports before they appear in updated SmPCs |
| Reaction to an OTC or herbal product | These products are less studied in large clinical trials and pharmacovigilance data is particularly valuable |
How to report
Community pharmacists can submit Yellow Card reports through several channels:
- Online: via yellowcard.mhra.gov.uk — the fastest route for most pharmacists
- Yellow Card app: available for iOS and Android, designed for quick mobile reporting
- Paper forms: available from the MHRA on request, though rarely used in 2026
- Through PMR systems: some pharmacy patient medication record systems have integrated Yellow Card submission functionality
A report typically takes 5–10 minutes to complete. The minimum information required is:
- A description of the suspected reaction
- The medicine(s) involved (including dose and duration where known)
- Patient details (age, sex — name is optional; reports can be anonymised)
- Reporter contact details (so the MHRA can follow up if needed)
Pharmacists do not need to prove causation. They do not need to perform a detailed clinical assessment. They need only to describe what they observed or what the patient reported.
Why pharmacy reporting matters
Community pharmacists see patients more frequently than any other healthcare professional — often weekly or fortnightly for repeat prescription collection. This puts them in a unique position to notice:
- Chronic ADRs that develop gradually and that patients may not connect to their medication
- ADRs in polypharmacy patients where interactions may be contributing to symptoms
- ADRs from OTC medicines that the patient's GP may not know about
- Patterns across multiple patients — a pharmacist who sees three patients in a month reporting the same new symptom on the same generic manufacturer's product may be identifying a batch-specific quality issue
According to PharmSee's tracker, community pharmacists across England serve approximately 13,147 registered pharmacy locations. The sheer volume of patient encounters across this network means that even a modest improvement in reporting rates could generate significant pharmacovigilance signal.
Black Triangle medicines
Medicines marked with a ▼ (inverted black triangle) in the BNF and on their packaging are subject to additional monitoring. The MHRA asks that healthcare professionals report all suspected ADRs for Black Triangle products, not just serious or unexpected ones.
As of 2026, the Black Triangle list includes recently licensed medicines across oncology, immunology, and metabolic disease — areas where the clinical trial populations were often small or unrepresentative of the broader UK patient mix. Community pharmacists dispensing these products play a direct role in the post-marketing safety evidence base.
Common barriers to reporting (and how to overcome them)
| Barrier | Reality |
|---|---|
| "I'm not sure the medicine caused it" | Certainty is not required. The MHRA explicitly states that suspected associations are sufficient |
| "The reaction is already in the SmPC" | Known reactions should still be reported if they seem more frequent or severe than expected — this is how the MHRA detects changes in ADR frequency |
| "It will take too long" | An online report takes 5–10 minutes. The Yellow Card app is designed for speed |
| "The GP should report it, not me" | Any healthcare professional can report. Waiting for the GP creates a gap — and the GP may not be aware of the reaction |
| "Nothing will happen" | MHRA Yellow Card data has contributed to safety label updates, product withdrawals, and regulatory action across dozens of medicines in recent years |
Professional obligation
The GPhC Standards of Conduct, Ethics and Performance state that pharmacists must "take action to protect patient safety". While Yellow Card reporting is voluntary in the strict legal sense — it is not a statutory requirement — the GPhC has indicated that a pharmacist who is aware of a suspected ADR and fails to report it may not be meeting their professional obligations to safeguard patient welfare.
In practical terms: reporting is expected, even if not legally mandated.
Further resources
- Browse pharmacy roles that involve pharmacovigilance responsibilities on PharmSee Jobs
- Compare pharmacist salary data across community, hospital, and regulatory settings
- Find pharmacies in your area on the pharmacy finder
Sources: MHRA Yellow Card Scheme guidance (yellowcard.mhra.gov.uk); GPhC Standards of Conduct, Ethics and Performance (pharmacyregulation.org); PharmSee pharmacy register data (13,147 pharmacies as of April 2026).